New Merck Names "The Fosamax Guy" As Its New Chief Medical Officer

The man apparently led a development efforts on Fosamax (a drug a theme of over 900 lawsuits alleging jaw line bone death, as a side effect of receiving it, longer term). Let's hope his instincts have softened given then. we trust he is better than which would suggest -- here is his before life, in summary fashion:
. . . .Dr. Rosenblatt has served as Dean of Tufts University School of Medicine given 2003. Prior to Tufts University, Dr. Rosenblatt hold a appointment of George R. Minot Professor of Medicine during Harvard Medical School as well as Chief of a Division of Bone as well as Mineral Metabolism Research during Beth Israel Deaconess Medical Center (BIDMC). He served as a President of BIDMC from 1999-2001. Previously, he was a Harvard Faculty Dean as well as Senior Vice President for Academic Programs during CareGroup as well as BIDMC as well as a owner of a Carl J. Shapiro Institute for Education as well as Research during Harvard Medical School as well as BIDMC.

Prior to that, he served as Director of a Harvard-MIT Division of Health Sciences as well as Technology. And earlier, he was Senior Vice President for Research during Merck Sharp & Dohme Research Laboratories where he co-led a worldwide development team for alendronate (FOSAMAX), Merck's bisphosphonate for osteoporosis as well as bone disorders. In leading most of Merck's international research efforts, he determined two vital simple research institutes. He also headed Merck Research's worldwide University as well as Industry Relations Department.

Dr. Rosenblatt is a target of a Fuller Albright Award for his work on parathyroid hormone as well as a Vincent du Vigneaud Award in peptide chemistry as well as biology, as well as a Chairmans Award from Merck. Dr. Rosenblatt perceived his undergraduate degree summa cum laude from Columbia as well as his M.D. magna cum laude from Harvard. His internship, residency, as well as endocrinology precision were all during a Massachusetts General Hospital. . . .
Well, we theory Merck just found a permanent consultant declare for the defense of these cases -- as well as probably cheaper (all-in) than his day-rate, too.